SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
OKLAHOMA CITY, Jan. 15, 2018 -- Cytovance® Biologics, Inc., a leading full-service biopharmaceutical contract manufacturer of mammalian and microbial biologics, announces and welcomes Edwin Miranda as Vice President of Quality. Edwin Miranda will be leading the full breadth of Cytovance’s Quality function.
“With over 33 years’ experience in the biopharmaceutical contract manufacturing industry, Edwin brings a depth of experience in quality assurance, encompassing solid & liquid oral dose, biologics and cosmetics,” said Dr. Jesse McCool, Sr. Vice President of Research & Development. “We are very fortunate to have such a well-seasoned and experienced executive join our team. Edwin’s knowledge and leadership skills will be tremendous assets to the Company.”
Prior to Cytovance, Edwin oversaw the Quality Assurance team in a successful FDA approval and launch of the New Drug Application (NDA) for Keppra®. He has served as Director of Quality or Vice President of Quality Assurance URL Mutual Pharmaceuticals, Inc., Legacy Pharmaceutical Packaging, and Piramal Critical Care, Inc. In these roles, he managed the quality systems, oversaw regulatory compliance functions, and developed a successful remediation plan to correct 483 observations, resulting in receipt of an Establishment Inspection Report (EIR) in good standing. Edwin, an army veteran, holds a B.S. in Biology & Chemistry from Angelo State University in San Angelo, TX.
“Edwin, comes to Cytovance in impeccable timing for Cytovance’s first PAI scheduled for February 2018,” commented Mike O’ Mara Sr. Vice President of Manufacturing Operations.” With a number of our clients getting ready to file BLA’s in 2018, Edwin’s expertise with FDA inspections will make him an invaluable addition to the Cytovance team.”
About Cytovance Biologics
Cytovance® Biologics is a biopharmaceutical contract manufacturing company specializing in the production of therapeutic proteins and antibodies from both mammalian cell culture and microbial fermentation. In addition to its cGMP manufacturing services, the company offers process development, cGMP cell banking and support services from its Oklahoma City state-of-the-art facilities.
Media Contact: Cheryl Tuck, [email protected]
